Targeting XCR1 facilitates trafficking
to lymph nodes and antigen-presenting
cells. (A,C) Time-course analysis of AF647 signal in mouse organs:
two mice per time point for mPAC and scFv; one mouse per time point
for scFv-mPAC. Mice were treated with 1 nmol of an AF647-labeled construct:
mPAC, anti-XCR1 scFv, or anti-XCR1 scFv-mPAC. The constructs were
subcutaneously (sc) administered over two equal volume injections,
one on each side of the tail base (n = 5 mice per
group for mPAC and scFv; n = 3 mice for scFv-mPAC).
(A) Representative images obtained after 2 h using an in vivo imaging
system (IVIS), showing AF647 signal from resected lymph nodes (inguinal
and axillary), spleen, and liver. Data represent the mean of whole-organ
radiant efficiency ± s.d. (B) Quantification of the AF647 signal
after 2, 24, and 48 h. (C) Flow cytometry analysis of the AF647 signal
after 2 h in single-cell splenocyte populations, including CD8+ dendritic cells (CD11c+CD8+), medullary
macrophages (CD11b+F4/80+), and T and B cells
(CD3+B220+). Data represent the mean of AF647+
cells ± s.d. All data are representative of two independent experiments.